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Abstract Burning mouth syndrome (BMS) is character-
ized by burning discomfort or pain in otherwise normal
oral mucosa. It is usually refractory. Treatment modalities
are scarce. Herein we report one case of primary disabling
BMS, previously refractory to multiple regimens, with
complete and persistent improvement with pramipexol, a
nonergot dopamine agonist which has high selectivity for
dopaminergic D2 receptors. We discuss potential patho-
physiological implications of our findings.
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Abbreviations
BMS Burning mouth syndrome
RLS Restless leg syndrome
PD Parkinson disease
Introduction
Burning mouth syndrome (BMS) is defined as the sensation
of burning or pain on the oral mucous membrane, without
evidence of abnormalities in the direct inspection, clinical
exam or subsidiary investigation [1]. Besides pain and
tingling, BMS is often characterized by dry mouth and
taste perversion [1, 2]. BMS is more prevalent among
postmenopausal women, affecting from 1.5 to 5.5% of this
population [3].
The BMS is a primary diagnosis. Several factors are
reported as being associated with burning mouth symp-
toms, including xerostomy, allergies to dentistry materials,
oral candidiasis, systemic nutritional deficiency (e.g. vita-
min B1, B2, B12, folic acid and zinc), diabetes, hormonal
disturbances, oral ulcer and periodontitis [1]. Nonetheless,
diagnosis of BMS requires the exclusion of secondary
causes.
Some studies suggest that BMS is a specific form of
cranial neuropathy, based on the pattern of sensorial find-
ings (hypoesthesia) [4], reduction of the nociceptive
threshold [5], as well as on neurophysiologic findings
(suggestive of a small fiber neuropathy) [6]. Other studies
suggest central nervous system abnormalities, including
changes in the blink reflex [7], larger availability of
dopamine receptors in the putamen [8] and reduction of 6-
[18F] fluorodopa recaptation on putamen [9].
The therapeutic options for BMS are scarce. Anecdotal
reports suggest the benefit of alfa-lipoic acid, an antioxi-
dant used in diabetic neuropathy, amisulpiride, a
neuroleptic of second generation that in low dosages pre-
sents dopaminergic activity, and of topic clonazepam [10–
13]. A recent study suggested that gabapentin is not
effective in the treatment of BMS [14].
Herein we report one case of refractory BMS with
complete improvement with pramipexol, a non-ergotic
dopaminergic agonist commonly used for Parkinson’s
disease. As exposed below, this medication was chosen
based on some clinical features of our patient that
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resembled what is commonly seen in restless leg syndrome.
Pramipexol has not been previously reported as potentially
effective for BMS. Accordingly, because the patient was
very refractory, and also because of some peculiar clinical
findings, we speculate on the pathophysiology of the
disease.
Case report
A 68-year-old woman reported daily continuous burning
feeling on the lateral and anterior site of her tongue and
lower lip for 3 years. The burning was of moderate inten-
sity (7 on a 10-point visual analogical scale), worsening by
the end of the afternoon. She reported important
improvement when speaking and moving the lower lip, as
well as when drinking cold water. She didn’t report any
worsening factor associated with worsening of the burning.
She noticed change in her taste sense, with lower tolerance
to heavy meals and increased burning after acid meals. She
did not complain of xerostomia and therefore the salivary
flow rate was not measured. She denied other medical
antecedents or use of medication.
Over the past 3 years, before seeking care with us, the
patient previously consulted four gastroenterologists. She
was submitted to a gastroscopy and Helicobacter pylori
infection was found. She had no improvement of the
burning sensation after proper treatment (Table 1).
The patient also had consulted five dentists. They
changed her dental prosthesis twice, tried periodontal
treatment and artificial saliva without meaningful results.
The intraoral inspection was normal. She used wear
superior total denture and inferior removable partial den-
ture, both in good conditions, without vertical dimension
lose or instability. She had no caries or periodontal diseases
in the anterior inferior teeth. Periapical and panoramic X-
ray exams were performed without alterations. General
physical and neurological exams were unremarkable.
Blood analysis was performed and blood routine, as well
as screening for vitamin deficiencies and ferritin were
within normal limits.
We established a diagnosis of refractory BMS and ini-
tiated treatment with pramipexol (0.125 mg at night—see
discussion for reasons that motivated the choice). Follow-
up information was obtained prospectively using a head-
ache calendar (measuring frequency and severity of pain,
use of rescue medications, etc.) and was contrasted to the
baseline. The information was independently reviewed by
one of us (JGS). After 1 week of treatment the patient
reported a 20% improvement (a decrease from seven to five
on visual analogical scale) and around 25% diminution in
the frequency of the symptoms. The dose was slowly
increased to 0.75 mg at night. After 4 weeks of treatment,
the burning symptoms disappeared. She remained symp-
tom free for several months. She did not report side effects.
Upon withdrawal of pramipexol, the symptoms relapsed
around 6 days after, with an intensity of pain around 60%
of the baseline. Since then, she has been using 0.75 mg at
night, with total control of the burning sensation. The
patient was followed for a year and she remains pain free,
with no significant tolerability issues.
Comments
This case of BMS showed two peculiar clinical charac-
teristics: (1) it worsened by the end of the day; (2) it
improved with the movement of the tongue. The circadian
fluctuation of the symptoms is a known feature of the BMS
[15]; however, the relief by moving the tongue is not a
notorious manifestation of this disease. Therefore, this
pattern of symptoms seemed similar to what is seen in
restless leg syndrome (RLS), a condition secondary due to
a dopaminergic dysfunction of the central nervous system.
RLS is characterized by lower limbs dysesthesias that
worsen by the end of the day and improve when moving
the legs [16, 17]. The prevalence of RLS in patients with
headache is high, [18], however, there are no data corre-
lating RLS with BMS.
Although the relationship between BMS and Parkin-
son’s disease is not universally accepted, the comorbidity
has been suggested. BMS is frequent among patients with
Parkinson’s disease (PD). In a study of 115 patients with
PD, burning mouth happened in 24% of them, incidence
prevalence 30 times greater than expected by chance only
[19].
The dopaminergic and nigrostriatal pathways are
important on pain modulation [20–22]. Non-specific
disturbances on the dopaminergic system have been doc-
umented in patients with BMS [8, 9]. The association of
BMS with RLS and PD, besides the improvement with
amisulpiride [11], point to a dopaminergic dysfunction in
BMS. All these facts support our therapeutic choice for the
reported case. Pramipexol is a non-ergotic dopaminergic
Table 1 Diagnostic criteria for burning mouth syndrome according
the International Classification of Headache Disorders (2004) [24]
Description:
An intraoral burning sensation for which no medical or dental cause
can be found.
Diagnostic criteria:
(a) Pain in the mouth present daily and persisting for most of the day.
(b) Oral mucosa is of normal appearance.
(c) Local and systemic diseases have been excluded.
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agonist, with predilection to dopaminergic D-2 receptors
[23, 24]. Our anedoctal finding should be confirmed by a
pilot study, and, if positive, by clinical trials. As a
cautionary note, since this is a report of a single case, we
cannot exclude that the therapeutic response to pramipexol
happened as a placebo effect, or merely as a coincidence.
Conflicts of Interest None.
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